APLS
Income statement / Annual
Last year (2023), Apellis Pharmaceuticals, Inc.'s total revenue was $396.59 M,
an increase of 425.83% from the previous year.
In 2023, Apellis Pharmaceuticals, Inc.'s net income was -$528.63 M.
See Apellis Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$396.59 M
|
$75.42 M
|
$66.56 M
|
$250.65 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$60.21 M |
$5.64 M |
$5.20 M |
$25.05 M |
$288.02 M |
$127.92 M |
$50.77 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$336.38 M |
$69.79 M |
$61.36 M |
$225.60 M |
-$288.02 M |
-$127.92 M |
-$50.77 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.85 |
0.93 |
0.92 |
0.9 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$354.39 M
|
$387.24 M
|
$420.87 M
|
$299.92 M
|
$220.97 M
|
$105.29 M
|
$40.30 M
|
$22.98 M
|
$13.73 M
|
$8.38 M
|
| General & Administrative
Expenses |
$500.82 M
|
$277.16 M
|
$176.77 M
|
$139.40 M
|
$67.05 M
|
$22.64 M
|
$10.46 M
|
$4.30 M
|
$6.36 M
|
$2.91 M
|
| Selling & Marketing
Expenses |
-$1.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$499.11 M
|
$277.16 M
|
$176.77 M
|
$139.40 M
|
$67.05 M
|
$22.64 M
|
$10.46 M
|
$4.30 M
|
$6.36 M
|
$2.91 M
|
| Other Expenses |
-$727,000.00 |
-$288,000.00 |
$1.36 M |
-$501,000.00 |
-$175,314.00 |
-$110,758.00 |
$11,542.00 |
$157,705.00 |
$6,284.00 |
$62,459.00 |
| Operating Expenses |
$853.50 M |
$664.40 M |
$597.64 M |
$439.32 M |
$288.02 M |
$127.92 M |
$50.77 M |
$27.28 M |
$20.09 M |
$11.29 M |
| Cost And Expenses |
$913.71 M |
$670.04 M |
$602.84 M |
$464.37 M |
$288.02 M |
$127.92 M |
$50.77 M |
$27.28 M |
$20.09 M |
$11.29 M |
| Interest Income |
$20.93 M |
$8.91 M |
$418,000.00 |
$4.16 M |
$5.11 M |
$2.96 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$29.58 M |
$32.63 M |
$13.24 M |
$29.94 M |
$5.28 M |
$2.51 M |
-$96,915.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.70 M
|
$1.49 M
|
$1.49 M
|
$859,000.00
|
$595,449.00
|
$127.93 M
|
$11,935.00
|
$27.28 M
|
$52.97 M
|
$6,594.00
|
| EBITDA |
-$515.42 M
|
-$584.50 M
|
-$533.01 M
|
-$209.43 M
|
-$282.84 M
|
-$125.07 M
|
-$50.60 M
|
-$27.28 M
|
$6.40 M
|
-$11.29 M
|
| EBITDA Ratio |
-1.3 |
-7.75 |
-8.01 |
-0.84 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-1.3
|
-7.88
|
-8.06
|
-0.85
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$9.38 M
|
-$56.89 M
|
-$209.73 M
|
-$129.30 M
|
-$16.69 M
|
-$25,249.00
|
-$142,150.00
|
$157,705.00
|
-$26.48 M
|
$62,459.00
|
| Income Before Tax |
-$526.50 M |
-$651.50 M |
-$746.00 M |
-$343.03 M |
-$304.71 M |
-$127.50 M |
-$51.01 M |
-$27.12 M |
-$46.52 M |
-$11.23 M |
| Income Before Tax Ratio
|
-1.33
|
-8.64
|
-11.21
|
-1.37
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$2.13 M |
$669,000.00 |
$352,000.00 |
$1.85 M |
$5.11 M |
-$533,324.00 |
$250,607.00 |
-$27.28 M |
-$26.54 M |
-$443,340.00 |
| Net Income |
-$528.63 M |
-$652.17 M |
-$746.35 M |
-$344.87 M |
-$309.82 M |
-$127.50 M |
-$51.01 M |
-$27.12 M |
-$46.52 M |
-$10.79 M |
| Net Income Ratio |
-1.33 |
-8.65 |
-11.21 |
-1.38 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-4.45 |
-6.15 |
-8.84 |
-4.59 |
-4.98 |
-2.34 |
-3.68 |
-1.5 |
-2.57 |
-0.6 |
| EPS Diluted |
-4.45 |
-6.15 |
-8.84 |
-4.59 |
-4.98 |
-2.34 |
-3.68 |
-1.5 |
-2.57 |
-0.6 |
| Weighted Average Shares
Out |
$118.68 M
|
$106.11 M
|
$84.42 M
|
$75.16 M
|
$62.23 M
|
$54.40 M
|
$13.87 M
|
$18.09 M
|
$18.09 M
|
$18.09 M
|
| Weighted Average Shares
Out Diluted |
$118.68 M
|
$106.11 M
|
$84.42 M
|
$75.16 M
|
$62.23 M
|
$54.40 M
|
$13.87 M
|
$18.09 M
|
$18.09 M
|
$18.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
